Open Access
Open access
том 19 издание 4 страницы 67-78

EPIGENETIC EFFECTS OF ENZASTAURIN – A NEW ASPECT IN THE MECHANISM OF ACTION OF AN ANTICANCER DRUG FROM PROTEIN KINASE INHIBITORS

Тип публикацииJournal Article
Дата публикации2020-09-02
Включен в RSCI
scimago Q4
БС1
SJR0.134
CiteScore0.6
Impact factor
ISSN18144861, 23123168
Cancer Research
Oncology
Краткое описание
The purpose of the study was to analyze the ability of five antitumor drugs from the pharmaceutical group of protein kinase inhibitors (gefitinib, imatinib, pazopanib, ponatinib and enzastaurin) to reactivate the expression of the epigenetically silenced GFP in HeLa TI cells, and to estimate the effect of epigenetically active drugs on: 1) acetylation and methylation of histones H3 and H4; 2) integral DNA methylation; 3) activity of HAT and HDAC1 enzymes; 4) expression levels of the genes encoding epigenetic regulation enzymes (DNMT1, DNMT3A, DNMT3B; SIRT1, HDAC1; SETD1A, SETD1B, SUV420H1, SUV420H2, SUV39H1, SUV39H2). Material and Methods . The epigenetic activity of antitumor drugs was determined using the HeLa TI test system, a population of HeLa cells with the retroviral vector containing the epigenetically silenced GFP. The level of integral DNA methylation was analyzed using MspI/HpaII methyl-sensitive restriction analysis. Histone modifications were analyzed by Western blotting with antibodies to acetylated and methylated histones H3 and H4. The total activity of HAT enzymes was analyzed using Histone Acetyltransferase Activity Assay Kit. Expression of the epigenetic enzyme genes was analyzed using real-time quantitative RT-PCR. Results . It was shown that only the enzyme inhibitor Cβ protein kinase enzastaurin had the ability to reactivate the expression of epigenetically silenced GFP in the HeLa TI cells. We showed that under the action of enzastaurin, the level of integral DNA methylation and expression of DNMT3A and DNMT3B DNA methyltransferase genes decreased. It was also found that enzastaurin reduced the expression levels of histone deacetylases HDAC1 and SIRT1, but did not affect the activity and expression levels of histone acetylases, the level of histone methylation (H3K4me3, H3K9me3, H3K27me3, H4K20me3), and the level of expression of the histone methyltransferases (SUV39H1, SUV39H2, SUV420H1, SUV420H2, SETD1A и SETD1B). Conclusion . The data obtained are important for clarifying the mechanisms of action of 5 protein kinase inhibitors, in particular with respect to enzastaurin, the protein kinase Cβ inhibitor, for which the ability to reactivate epigenetically silent genes due to the effect on DNA methylation and histone acetylation was demonstrated.
Найдено 

Вы ученый?

Создайте профиль, чтобы получать персональные рекомендации коллег, конференций и новых статей.
Метрики
0
Поделиться
Цитировать
ГОСТ |
Цитировать
Maksimova V. et al. EPIGENETIC EFFECTS OF ENZASTAURIN – A NEW ASPECT IN THE MECHANISM OF ACTION OF AN ANTICANCER DRUG FROM PROTEIN KINASE INHIBITORS // Siberian Journal of Oncology. 2020. Vol. 19. No. 4. pp. 67-78.
ГОСТ со всеми авторами (до 50) Скопировать
Maksimova V., Makus J. V., Usalka O. G., Lylova E. S., Bugaeva P. E., Zhidkova E. M., Fedorov D. A., Lizogub O. P., Lesovaya E. A., Belitsky G. A., Yakubovskaya M. G., Kirsanov K. I. EPIGENETIC EFFECTS OF ENZASTAURIN – A NEW ASPECT IN THE MECHANISM OF ACTION OF AN ANTICANCER DRUG FROM PROTEIN KINASE INHIBITORS // Siberian Journal of Oncology. 2020. Vol. 19. No. 4. pp. 67-78.
RIS |
Цитировать
TY - JOUR
DO - 10.21294/1814-4861-2020-19-4-67-78
UR - https://www.siboncoj.ru/jour/article/view/1531
TI - EPIGENETIC EFFECTS OF ENZASTAURIN – A NEW ASPECT IN THE MECHANISM OF ACTION OF AN ANTICANCER DRUG FROM PROTEIN KINASE INHIBITORS
T2 - Siberian Journal of Oncology
AU - Maksimova, Varvara
AU - Makus, J V
AU - Usalka, Olga G
AU - Lylova, E S
AU - Bugaeva, P E
AU - Zhidkova, Ekaterina M.
AU - Fedorov, D A
AU - Lizogub, O P
AU - Lesovaya, Ekaterina A.
AU - Belitsky, G A
AU - Yakubovskaya, Marianna G.
AU - Kirsanov, Kirill I.
PY - 2020
DA - 2020/09/02
PB - Tomsk Cancer Research Institute
SP - 67-78
IS - 4
VL - 19
SN - 1814-4861
SN - 2312-3168
ER -
BibTex |
Цитировать
BibTex (до 50 авторов) Скопировать
@article{2020_Maksimova,
author = {Varvara Maksimova and J V Makus and Olga G Usalka and E S Lylova and P E Bugaeva and Ekaterina M. Zhidkova and D A Fedorov and O P Lizogub and Ekaterina A. Lesovaya and G A Belitsky and Marianna G. Yakubovskaya and Kirill I. Kirsanov},
title = {EPIGENETIC EFFECTS OF ENZASTAURIN – A NEW ASPECT IN THE MECHANISM OF ACTION OF AN ANTICANCER DRUG FROM PROTEIN KINASE INHIBITORS},
journal = {Siberian Journal of Oncology},
year = {2020},
volume = {19},
publisher = {Tomsk Cancer Research Institute},
month = {sep},
url = {https://www.siboncoj.ru/jour/article/view/1531},
number = {4},
pages = {67--78},
doi = {10.21294/1814-4861-2020-19-4-67-78}
}
MLA
Цитировать
Maksimova, Varvara, et al. “EPIGENETIC EFFECTS OF ENZASTAURIN – A NEW ASPECT IN THE MECHANISM OF ACTION OF AN ANTICANCER DRUG FROM PROTEIN KINASE INHIBITORS.” Siberian Journal of Oncology, vol. 19, no. 4, Sep. 2020, pp. 67-78. https://www.siboncoj.ru/jour/article/view/1531.